Cipla’s wholly owned subsidiary - Cipla Holding B.V., has acquired 100% stake in Celeris d.o.o., Croatia. Celeris d.o.o. is the distributor of company’s products in Croatia.
Cipla focuses on development of new formulations and has a wide range of pharmaceutical products. It offers prescription drugs, bulk drugs, animal products and pesticides. It also offers a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products.
The company has reported 24.79% fall in its net profit at Rs 376.03 crore for the second quarter ended September 30, 2013 as compared to Rs 500.01 crore for the same quarter in the previous year. However, total income of the company has increased by 6.59% at Rs 2411.96 crore for quarter under review as compared to Rs 2262.74 crore for the quarter ended September 30, 2012.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: